Similar articles

• Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.

  Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D. Taboada M, et al. J Antimicrob Chemother. 2016 Apr;71(4):862-70. doi: 10.1093/jac/dkv415. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702925 Review.
• Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.

  Rank DR, Friedland HD, Laudano JB. Rank DR, et al. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii53-9. doi: 10.1093/jac/dkr099. J Antimicrob Chemother. 2011. PMID: 21482570 Clinical Trial.
• FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

  Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators. Low DE, et al. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097. J Antimicrob Chemother. 2011. PMID: 21482568 Clinical Trial.
• FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

  File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators. File TM Jr, et al. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096. J Antimicrob Chemother. 2011. PMID: 21482566 Clinical Trial.
• Summary of ceftaroline fosamil clinical trial studies and clinical safety.

  File TM Jr, Wilcox MH, Stein GE. File TM Jr, et al. Clin Infect Dis. 2012 Sep;55 Suppl 3:S173-80. doi: 10.1093/cid/cis559. Clin Infect Dis. 2012. PMID: 22903949 Review.